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GUEST EDITORIAL
Intravesical therapy in the management ofsuperficial transitional cell
carcinoma of the bladder: the experience of the EORTC GU Group
D. Newling
Princess Royal Hospital, Salthouse Road, Hull HU8 9HE, UK.
The majority of transitional cell carcinomas of the bladder
present as superficial tumours. After primary treatment,
which usually comprises transurethral resection (TUR) of the
tumour, some 60% of superficial lesions will recur (Greene et
al., 1973; Lerman et al., 1970; Schulman et al., 1976). The
origin of this high recurrence rate is probably the presence of
new tumours following widespread field change over the
whole of the bladder from previous exposure to carcinogens
in the urine. An alternative theory suggests that the recur-
rence rate is high because of the implantation of malignant
cells at the time of primary resection. Whichever theory is
subsequently proved to be true, if either of them can, it
would seem inescapable that the high rate of recurrence of
transitional cell carcinoma should be preventable by the ap-
plication of topical intravesical therapy. Whether the cells are
floating or fixed, they should be susceptible to cytostatic
therapy administered in this way.
For a number of years it has been known that the instilla-
tion of certain agents into the bladder can reduce the
incidence of recurrent tumours after primary resection.
Equally it has been known that certain agents, some the
same, some different, may be used in the chemoresection of
tumours not amenable to simple surgery (Riddle, 1973;
Mishina et al., 1975). Intravesical therapy of transitional cell
carcinoma of the bladder is, therefore, either therapeutic or
prophylactic. It is used either to ablate tumours or render
them more suitable for surgical treatment or to prevent
tumour recurrence after surgery. The term 'superficial blad-
der tumour' generally includes both TA and Tl tumours as
well as carcinoma in situ. These three different varieties of
bladder tumour have widely different prognoses and they
may require different regimes of intravesical therapy.
Over the past 12 years the EORTC GU Group has carried
out a series of studies of prophylactic intravesical therapy of
superficial bladder cancer to investigate the appropriate
choice of drugs and the optimal conditions and schedules for
intravesical therapy to prevent recurrence after surgical resec-
tion. We have also investigated the choice of the most
effective agents and regimens to ablate superficial tumours
and to assess if there is always a place of prophylaxis after
successful ablation. It is now timely to consider what has
been learnt from these studies.
The first study was a prospective, randomised phase III
clinical trial of thiotepa (30 mg weeky for 1 month and
monthly for 1 year) versus VM26 (50 mg weekly for 1 month
and monthly for 1 year) versus TUR alone in the manage-
ment of superficial TA, TI bladder cancer. The aims of the
study were to compare the disease-free interval in the three
regimens, the recurrence rate and to assess the number of
patients with an increase in tumour stage. The disease-free
interval was defined as the interval between the initial trans-
urethreal resection and the first biopsy proven recurrence.
The recurrence rate was defined as the number of positive
cystoscopies divided by the total duration of follow-up. At
the conclusion of this study an analysis was carried out of
the prognostic factors determining the rate of recurrence and
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progression in superficial bladder cancer and these prognostic
factors were subsequently used to stratify patients in later
studies. This study showed that thiotepa was an extremely
active agent in the prophylaxis of recurrent bladder tumour,
being more active than intravesical VM26 and much more
efficient than TUR alone. There was no difference in the time
to first recurrence but there was a difference in the subse-
quent recurrence rate, with thiotepa being the most active
prophylactic agent.
The prognostic factor analysis from this study highlighted
certain groups of patients who are at a high risk ofdevelop-
ing recurrence. These are patients with four or more tumours
at presentation, patients who have dysplasia or carcinoma in
situ in random biopsies of the bladder, patients who have a
history of recurrence before their recruitment to the study
and patients with tumours of high grade or large size (5 cm
or more) (Dalesio et al., 1983).
Following the first study and a number of pilot studies it
seemed that the best regimen for intravesical therapy to
prevent the recurrence of superficial bladder tumours should
involve an intensive 4-6 weeks of treatment followed by
monthly prophylaxis for 6 months to 1 year.
The next protocol was for patients with recurrent tumours
only and compared intravesical thiotepa (50 mg in 50 ml
weekly for 1 month and monthly for 1 year), adriamycin
(50 mg in 50 ml weekly for 1 month and monthly for 1 year)
and cisplatinum (50 mg in 50ml weekly for 1 month and
monthly for 1 year). It showed adriamycin and thiotepa to be
equally effective in the prevention of recurrence of superficial
bladder cancer and the recurrence rate in those two arms of
the study was the same as the recurrence rate for the thiotepa
arm of the first study; the cisplatinum was discontinued
because of anaphylactic reactions.
The third study in patients with TA or Tl tumours com-
pared the intravesical adriamycin regimen with intravesical
epodyl (1.13 g weekly for 1 month and monthly for 1 year)
and the study contained, once more, a third arm of patients
who were treated by transurethral resection alone, since in
the first study there had been no difference in the three arms
with regard to time to first recurrence. This study differed
from previous studies in that the end-point was not the time
to the first recurrence, but either the first recurrence after 1
year of treatment, or progression. In this way it was hoped to
overcome the confusion between residual and truly recurrent
tumours and also to give the intravesical agents time to act.
Therefore, if patients recurred during the first year they
received a further course of treatment following transurethral
resection where appropriate, but the total length of treatment
did not exceed 12 months.
Half-way through the study, it was quite clear that patients
who were receiving intravesical chemotherapy had a very
much lower rate of recurrence than those patients in the
TUR alone arm and that arm of the study was closed before
the entire study had been recruited. The recurrence rates in
the two arms, where the patients received intravesical
chemotherapy, were statistically inseparable and there
appeared to be no difference between the two agents,
adriamycin and epodyl, in this situation (Kurth et al., 1985).
The EORTC GU Group was only one group carrying out
Br. J. Cancer (1990), 61, 497-499 Q'I Macmillan Press Ltd., 1990498 D. NEWLING
such studies throughout the world and at this time it seemed
that four agents were equally effective in preventing recur-
rence ofbladder tumours: epodyl, thiotepa, mitomycin C and
adriamycin. All these agents had been shown to be effective
in ablating superficial bladder tumour in phase II studies and
all had been shown to reduce the recurrence of superficial
tumours in phase III studies. There were some differences in
the toxicity of the regimes and quite a considerable difference
in the cost of the agents.
The toxicity of intravesical instillation may be either local
or systemic. The local toxicity is chemical or bacterial cystitis
and work by Pavone and Jacobi (1982) had suggested that
this was more common where patients were treated
immediately after resection. Systemic side-effects occur very
rarely with the larger molecular weight agents but the smaller
molecular weight compounds, such as thiotepa and epodyl,
were absorbed following transurethral resections.
In the next two studies we assessed the place of early
treatment and clinicians could choose whether they used
either mitomycin or adriamycin, and both the agents were to
be studied in patients with new or recurrent, single or multi-
ple superficial tumours. The two studies looked at the efficacy
and toxicity of early (6 h after TUR) or delayed (7-15 days
after TVR) instillation in a prospective manner and also the
advantage of intermediate or long-term prophylaxis.
There was a marginal advantage for early instillation with
long-term prophylaxis in those patients treated with
adriamycin but for mitomycin the time of instillation and the
addition of maintenance therapy appear, at this stage, to
make little difference. However, early instillation of
adriamycin intravesically was associated with a high
incidence of chemical cystitis which led to withdrawal from
the study of some 4% of patients because of delay or cessa-
tion of treatment and its overall advantage was less because
of this.
Intravesical instillation of BCG had been used for many
years in both the therapeutic and prophylactic treatment of
superficial bladder cancer (Morales et al., 1976; Lamm et al.,
1980; Brosman, 1982). It had also been shown to be very
effective in the therapy of carcinoma in situ (Herr et al.,
1983). The mode of action of BCG is still not fully under-
stood but it would seem to employ an immunotherapeutic
mechanism. BCG has been shown to share some common
antigenicity with certain tumour cells. It is a stimulant of the
reticulo-endothelial system and of the antibody response, and
it increases the delayed hypersensitivity response (Robinson,
1984). By 1984 a number of phase II studies of intravesical
BCG in the treatment and prophylaxis of superficial bladder
cancer had been completed. There were, however, very few
phase III studies and it was therefore decided to mount a
phase III study of intravesical BCG (6-weekly instillations to
be repeated if recurrence at 3 months) versus intravesical
mitomycin C (30 mg in 50 ml saline; month 1, weekly;
months 2-6, monthly). The end-point was first recurrence
after completion of intravesical treatment. There was, and
still is, considerable debate as to what is the most effective
strain of BCG but we elected to use BCG RIVM, a strain
produced by the Dutch National Institute of Public Health
and Environmental Hygiene.
Both intravesical BCG RIVM and intravesical mitomycin
C were equally effective in preventing recurrence of
superficial bladder tumour. The BCG strain was very much
cheaper but intravesical BCG was marginally more toxic
locally than mitomycin (Debruyne et al., 1986).
Four studies were also started in 1986, all based on the
prognostic factor analysis of earlier studies and two of them
attempting to answer a new question. A phase II study of
intravesical Connaught BCG for primary or secondary car-
cinoma in situ is in progress. We are also studying whether or
not an intravesical agent which is shown to be effective
therapeutically is also effective in the same patient as pro-
phylaxis against recurrence. There were two agents the
Group were particularly interested in this respect: mitomycin
C and 4-epirubicin, a new analogue of the parent adriamcyin
compound used in previous studies. The two studies were
written as combined phase II/phase III studies. The initial
therapy with one of the drugs is administered after all but
one lesions in the bladder have been removed, the one being
left as a marker lesion. The bladder is examined at 12 weeks,
the marker lesion, if it remains, resected or its area biopsied
and the patient is then randomised subsequently to receive
either maintenance or no maintenance therapy with the same
drug.
The patients all have multiple, primary or recurrent
tumour and, therefore, should naturally have a high rate of
recurrence. The studies are extremely slow to recruit, partly
due to some institutions having ethical problems over the
leaving of a marker lesion and partly because the studies are
naturally quite complex. They have, in fact, already been
curtailed and reduced in the number of patients to be
studied. Nevertheless, it is hoped that both will ultimately be
phase II/phase III studies, although all the objectives may
not be achieved. It is hoped that the primary question of the
relationship between a therapeutic effect and a prophylactic
effect of a give agent administered intravesically can be
assessed.
The final study ongoing at the present time is a ran-
domised phase III study in patients with single, new or
recurrent TA/Ti tumours who, following transurethral resec-
tion, receive a single instillation of 80mg of 4-epirubicin
intravesically. In this study it was decided to re-examine the
patient cystoscopically after one month in order to ensure the
adequacy of transurethral resection. This study has now
recruited over 400 patients and will be closed when a replace-
ment study is ready. This study is investigating, with possibly
the most active agent at our disposal, the suggestion first
made by Burnard et al. (1976) that in patients with a tumour
with good prognostic factors a single intravesical instillation
is adequate to prevent recurrence.
The EORTC Group has shown that there are a number of
active agents which may be used intravesically to prevent
recurrence of superficial bladder tumours. These are thiotepa,
epodyl, adriamycin, mitomycin, 4-epirubicin and BCG. All
these agents are effective in ablative therapy of widely recur-
rent tumours and many of them, particularly BCG, are
effective in the treatment of primary carcinoma in situ. While
an appropriate regimen with regard to the frequency of
instillation seems to have been arrived at for chemo-
prophylaxis, there are a number of questions with regard to
the maximum efficacy of each individual agent in the urine
and whether or not buffering or alteration of the constituents
of the urine may affect that, which have yet to be studied.
There has been no evidence in any of the studies carried out
on over 2,000 patients that any of the intravesical agents are
effective in preventing progression to a higher stage (Greene
et al., 1984; Somerville et al., 1985).
We now feel that the place, mechanism of administration
and usefulness of intravesical chemotherapy have been quite
clearly defined. The time has come when a more detailed
look into the prevention of bladder cancer by removing
aetiological agents and by neutralising early pre-cancerous
change in cells of the transitional cell urothelium is probably
the only way that a major impact is going to be made in
reducing the incidence of invasive disease. The complete
elimination of tobacco abuse would be a major step forward
in the prevention of bladder cancer and more detailed
analyses of abnormal urinary constituents in patients who
have developed tumours may help to identify other agents
which could be removed. It seems likely, for instance, that
there are still a number of metabolites of tryptophan and
other amino acids that need to be examined in this respect.
Stabilisation of the urothelium with retinoids and other
vitamin derivatives may be a preventive measure which needs
exploring further, and strengtheninig of the aminoglycans
layer to prevent urinary constituents from damaging the cell
is another possible avenue of research. Early identification of
changes in transitional cell epithelium before rapid prolifera-
tion of mutated cells may be of benefit and perhaps new
therapeutic weapons will be useful against these cells.
The careful and sensible use of intravesical chemotherapyINTRAVESICAL THERAPY 499
is probably only the tip of the iceberg in our efforts to
conquer bladder cancer. It has its role in a clearly defined
group of patients, it can be simply administered in ordinary
district hospitals on a day case basis and the toxicity is
minimal although the expense is not. It is, however, sad to
relate that for all our efforts the mortality from bladder
cancer is still high and we seem still incapable of preventing
the emergence of invasive tumours by the present methods
available to us.
I acknowledge with great pleasure and gratitude the efficiency and
endeavour of the following who were the co-ordinators of the studies
described in this article: Professor C. Schulman, Brussels; Mr
M.R.G. Robinson, Pontefract; Professor L. Denis, Antwerp; Profes-
sor K.H. Kurth, Amsterdam; Dr C. Bouffioux, Liege; Professor F.
Debruyne, Nijmegen; Dr G. Jakse, Munich; Dr W. Oosterlinck,
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